The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.
The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback